✨
AI Summary
- GLP-1/GIP agonists show promise for CVD, Type 2 Diabetes, and obesity.
- Valacyclovir is explored as a potential treatment for Alzheimer's disease.
- Strategies to address weight regain post-medication and encourage deprescribing are discussed.